Sun Pharma has launched Cequa (cyclosporine ophthalmic solution) for treating dry eye disease in the US.
Cequa, the highest concentration of cyclosporine for ophthalmic use approved by the FDA, is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 million people in the US.
Cequa is the first and only FDA-approved cyclosporine treatment delivered with nanomicellar (NCELL) technology, which helps to improve the bioavailability and physicochemical stability of cyclosporine, resulting in improved ocular tissue penetration.
“The US launch of Cequa, the third product in our growing ophthalmic portfolio, marks the availability of a truly innovative treatment option for patients with dry eye disease – an area with a high unmet medical need,” said Abhay Gandhi, CEO North America, Sun Pharma.
“As a higher concentration cyclosporine product than what is currently commercially available, delivered with NCELL technology, Cequa continues to demonstrate our leadership in creating novel formulations of proven medications.”